Galectin Therapeutics Inc. (NASDAQ:GALT – Free Report) – Analysts at HC Wainwright lowered their Q2 2026 EPS estimates for shares of Galectin Therapeutics in a research note issued on Friday, May 15th. HC Wainwright analyst M. Keller now expects that the company will post earnings per share of ($0.09) for the quarter, down from their previous estimate of ($0.07). The consensus estimate for Galectin Therapeutics’ current full-year earnings is ($0.31) per share. HC Wainwright also issued estimates for Galectin Therapeutics’ Q3 2026 earnings at ($0.10) EPS and FY2026 earnings at ($0.37) EPS.
Galectin Therapeutics (NASDAQ:GALT – Get Free Report) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.02).
Get Our Latest Stock Report on GALT
Galectin Therapeutics Stock Performance
Galectin Therapeutics stock opened at $2.19 on Tuesday. Galectin Therapeutics has a 52-week low of $1.22 and a 52-week high of $7.13. The firm has a 50 day moving average price of $2.56 and a two-hundred day moving average price of $3.66. The firm has a market cap of $144.17 million, a price-to-earnings ratio of -5.34 and a beta of 0.45.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the stock. Marshall Wace LLP acquired a new position in shares of Galectin Therapeutics during the 2nd quarter valued at $64,000. Cetera Investment Advisers acquired a new position in shares of Galectin Therapeutics during the 4th quarter valued at $59,000. Bank of America Corp DE lifted its position in shares of Galectin Therapeutics by 101.4% during the 4th quarter. Bank of America Corp DE now owns 38,358 shares of the company’s stock valued at $49,000 after acquiring an additional 19,316 shares during the period. Royal Bank of Canada lifted its position in shares of Galectin Therapeutics by 1,197.3% during the 4th quarter. Royal Bank of Canada now owns 6,175 shares of the company’s stock valued at $25,000 after acquiring an additional 5,699 shares during the period. Finally, Renaissance Technologies LLC acquired a new position in shares of Galectin Therapeutics during the 1st quarter valued at $413,000. Institutional investors and hedge funds own 11.68% of the company’s stock.
Galectin Therapeutics Company Profile
Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.
Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.
Featured Stories
- Five stocks we like better than Galectin Therapeutics
- Why Trump’s Amazon Stock Sale May Not Matter at All
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
